Agranulocytosis secondary to antineoplastic chemotherapy is a severe, life-threatening hematologic condition characterized by a profound reduction in the number of circulating granulocytes, specifically neutrophils, to a level below 500 cells per microliter (µL), and often below 100 cells/µL. This condition is a direct consequence of cytotoxic chemotherapy agents, which are designed to target rapidly dividing cells but inadvertently suppress the hematopoietic stem cells in the bone marrow. The resulting neutropenia compromises the body's primary defense against bacterial and fungal infections. The severity and duration of agranulocytosis are typically dependent on the type of chemotherapy agent, the dosage, and the patient's underlying bone marrow reserve. Clinical management requires vigilant monitoring, the potential use of granulocyte colony-stimulating factors (G-CSFs) to accelerate marrow recovery, and immediate empirical broad-spectrum antibiotic therapy if the patient develops a fever (febrile neutropenia), as infections can progress to septic shock rapidly in this population.
Explicitly document the Absolute Neutrophil Count (ANC) to support the diagnosis of agranulocytosis.
Example: Patient presents with an Absolute Neutrophil Count (ANC) of 0.3 x 10^9/L (300 cells/mm3), meeting clinical criteria for agranulocytosis secondary to his recent cycle of cyclophosphamide. This acute hematological toxicity requires immediate cessation of chemotherapy and initiation of G-CSF.
Billing Focus: The documentation of a specific ANC below 500 cells/mm3 provides the clinical evidence necessary to support the severity of D70.1 and justifies high-complexity medical decision-making for billing.
Identify the specific antineoplastic agent causing the agranulocytosis to facilitate the use of required T-codes.
Example: Agranulocytosis diagnosed today with ANC at 250/uL, determined to be an adverse effect of Fluorouracil (5-FU) therapy for Stage IV colorectal cancer. We will proceed with T45.1X5A as the secondary code to identify the causative agent as an antineoplastic drug.
Billing Focus: ICD-10-CM guidelines require an additional code from category T45.1 to identify the specific drug; failure to include this external cause code can lead to claim denials.
Distinguish between simple neutropenia and agranulocytosis based on the severity of the count and clinical presentation.
Example: Documentation confirms agranulocytosis rather than mild neutropenia, as ANC is critically low at 150/mm3 following adjuvant chemotherapy for breast cancer. Patient is at extreme risk for opportunistic infections.
Billing Focus: D70.1 is a more specific and higher-weighted code than D70.9 (Neutropenia, unspecified). Accurate coding depends on using the term agranulocytosis when the ANC is under 500.
Always document the presence or absence of fever to determine if the additional code for febrile neutropenia is required.
Example: Agranulocytosis secondary to chemotherapy (ANC 400); patient is currently febrile with a temperature of 102.4F. Coding both D70.1 and R50.81 for febrile neutropenia to capture the full clinical syndrome.
Billing Focus: Reporting R50.81 alongside D70.1 identifies a more complex clinical encounter, often justifying a level 5 E/M code (99215) for an established patient.
Specify the encounter type such as initial, subsequent, or sequela when using the mandatory T-code for the causative agent.
Example: Agranulocytosis secondary to Docetaxel treatment; this is the initial encounter for this adverse effect. Patient admitted for IV antibiotics and neutropenic precautions. Code T45.1X5A applied for the initial encounter.
Billing Focus: The 7th character for the adverse effect code (A, D, or S) must match the episode of care; mismatching the episode of care with the clinical notes is a common source of billing errors.
Standard code for managing chemotherapy side effects including agranulocytosis without severe complications.
Used when agranulocytosis is accompanied by fever or signs of infection requiring intensive management.
The essential diagnostic tool for identifying the Absolute Neutrophil Count (ANC).
Used for rapid monitoring of total white cell counts between full CBCs.
The primary pharmacological treatment used to stimulate neutrophil production in agranulocytosis.
The procedure that typically causes the condition represented by D70.1.
Used if the agranulocytosis does not recover as expected to rule out other marrow pathologies.
Required for patients admitted with febrile neutropenia or severe agranulocytosis.
Prophylactic or therapeutic agent used to manage the duration of agranulocytosis.
Used when a patient is referred to a specialist due to newly discovered low counts after chemo.